Pyxis Oncology (PYXS) Asset Utilization Ratio (2024 - 2026)
Pyxis Oncology (PYXS) posted quarterly Asset Utilization Ratio of 0.14 for Q4 2025, up 53.48% year-over-year from 0.09 in Q4 2024, and up 470.43% quarter-over-quarter from 0.02 in Q3 2025.
Pyxis Oncology (PYXS) Asset Utilization Ratio (2024 - 2026) Analysis & Trends
Pyxis Oncology (PYXS) has reported Asset Utilization Ratio for 2 consecutive years, with 0.14 the latest figure, recorded in Q4 2025.
- In Q4 2025, Asset Utilization Ratio rose 53.48% year-over-year to 0.14; the TTM figure through Dec 2025 stood at 0.14 (up 53.48% YoY), while the FY2025 annual figure was 0.11, up 14.2% from the prior year.
- Asset Utilization Ratio improved to 0.14 in Q4 2025 per PYXS's latest filing, from 0.02 in the prior quarter.
- Across five years, Asset Utilization Ratio topped out at 0.14 in Q4 2025 and bottomed at 0.02 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Asset Util. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.90 Bn | 132.05 Bn | 2.84 Bn | 0.47 |
| 2 | Regeneron Pharmaceuticals | 86.70 Bn | 78.71 Bn | 3.93 Bn | 0.38 |
| 3 | Argenx Se | 65.73 Bn | 60.55 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.33 Bn | 53.19 Bn | 52.00 Mn | 0.20 |
| 5 | BeOne Medicines | 42.16 Bn | 37.07 Bn | 1.53 Bn | 0.69 |
| 6 | Alnylam Pharmaceuticals | 31.72 Bn | 28.42 Bn | 992.69 Mn | 0.90 |
| 7 | BioNTech SE | 28.27 Bn | 9.88 Bn | 668.28 Mn | 0.13 |
| 8 | Insmed | 27.61 Bn | 26.45 Bn | 358.27 Mn | 0.54 |
| 9 | Royalty Pharma | 27.25 Bn | 26.41 Bn | - | 0.13 |
| 10 | Pyxis Oncology | 195.81 Mn | 162.82 Mn | - | 0.19 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 0.19 |
| Dec 31, 2025 | 0.14 |
| Sep 30, 2025 | 0.02 |
| Jun 30, 2025 | 0.02 |
| Dec 31, 2024 | 0.09 |